Observational studies have shown inconsistent findings of the relationships between aspirin use and the risk of Alzheimer’s disease (AD).
Objective:
Since residual confounding and reverse causality were challenging issues inherent in observational studies, we conducted a 2-sample Mendelian randomization analysis (MR) to investigate whether aspirin use was causally associated with the risk of AD.
Methods:
We conducted 2-sample MR analyses utilizing summary genetic association statistics to estimate the potential causal relationship between aspirin use and AD. Single-nucleotide variants associated with aspirin use in a genome-wide association study (GWAS) of UK Biobank were considered as genetic proxies for aspirin use. The GWAS summary-level data of AD were derived from a meta-analysis of GWAS data from the International Genomics of Alzheimer’s Project (IGAP) stage I.
Results:
Univariable MR analysis based on these two large GWAS data sources showed that genetically proxied aspirin use was associated with a decreased risk of AD (Odds Ratio (OR): 0.87; 95%CI: 0.77–0.99). In multivariate MR analyses, the causal estimates remained significant after adjusting for chronic pain, inflammation, heart failure (OR = 0.88, 95%CI = 0.78–0.98), or stroke (OR = 0.87, 95%CI = 0.77–0.99), but was attenuated when adjusting for coronary heart disease, blood pressure, and blood lipids.
Conclusion:
Findings from this MR analysis suggest a genetic protective effect of aspirin use on AD, possibly influenced by coronary heart disease, blood pressure, and lipid levels.
Alzheimer’s Association (2021) 2021 Alzheimer’s disease facts and figures. Alzheimers Dement17, 327–406.
2.
TorreJ, Gonzalez-LimaF (2021) The FDA approves Aducanumab for Alzheimer’s disease, raising important scientific questions. J Alzheimers Dis82, 881–882.
EtminanM, GillS, SamiiA (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: Systematic review and meta-analysis of observational studies. BMJ327, 128.
10.
NilssonSE, JohanssonB, TakkinenS, BergS, ZaritS, McClearnG, MelanderA (2003) Does aspirin protect against Alzheimer’s dementia? A study in a Swedish population-based sample aged≥80 years. Eur J Clin Pharmacol59, 313–319.
11.
SzekelyC, GreenR, BreitnerJ, ØstbyeT, BeiserA, CorradaM, DodgeH, GanguliM, KawasC, KullerL, PsatyB, ResnickS, WolfP, ZondermanA, Welsh-BohmerK, ZandiP (2008) No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurol70, 2291–2298.
12.
KelleyBJ, McClureLA, UnverzagtFW, KisselaB, KleindorferD, HowardG, WadleyVG (2015) Regular aspirin use does not reduce risk of cognitive decline. J Am Geriatr Soc63, 390.
13.
GrodsteinF, SkarupskiKA, BieniasJL, WilsonRS, BennettDA, EvansDA (2008) Anti-inflammatory agents and cognitive decline in a bi-racial population. Neuroepidemiology30, 45–50.
14.
ArvanitakisZ, GrodsteinF, BieniasJ, SchneiderJ, WilsonR, KellyJ, EvansD, BennettDA (2008) Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology70, 2219–2225.
15.
SzekelyCA, BreitnerJC, FitzpatrickAL, ReaTD, PsatyBM, KullerLH, ZandiPP (2008) NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type. Neurology70, 17–24.
16.
WaldsteinSR, WendellCR, SeligerSL, FerrucciL, MetterEJ, ZondermanAB (2010) Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging. J Am Geriatr Soc58, 38–43.
17.
MandasA, MereuRM, CatteO, SabaA, SerchisuL, CostaggiuD, PeirettiE, CaminitiG, VinciM, CasuM, PiluduS, FossarelloM, ManconiPE, DessiS (2014) Cognitive impairment and age-related vision disorders: Their possible relationship and the evaluation of the use of aspirin and statins in a 65 years-and-over Sardinian population. Front Aging Neurosci6, 309.
18.
CôtéS, CarmichaelPH, VerreaultR, LindsayJ, LefebvreJ, LaurinD (2012) Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer’s disease. Alzheimers Dement8, 219–226.
19.
NguyenTNM, ChenLJ, TraresK, StockerH, HolleczekB, BeyreutherK, BrennerH, SchoettkerB (2021) Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: Results from two large cohort studies. Alzheimers Res Ther14, 75.
20.
RyanJ, StoreyE, MurrayAM, WoodsRL, WolfeR, ReidCM, NelsonMR, ChongTT, WilliamsonJD, WardSA, LockeryJE, OrchardSG, TrevaksR, KirpachB, NewmanAB, ErnstME, McNeilJJ, ShahRC (2020) Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline, Neurology95, e320–e331.
21.
GorenfloMP, DavisPB, KendallEK, OlakerVR, KaelberDC, XuR (2022) Association of aspirin use with reduced risk of developing Alzheimer’s disease in elderly ischemic stroke patients: A retrospective cohort study. J Alzheimers Dis91, 1–8.
22.
SmithGD, EbrahimS (2003) ‘Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease?Int J Epidemiol32, 1–22.
23.
SmithGD, HemaniG (2014) Mendelian randomization: Genetic anchors for causal inference in epidemiological studies, Hum Mol Genet23, R89–R98.
24.
SheehanNA, DidelezV, BurtonPR, TobinMD (2008) Mendelian randomisation and causal inference in observational epidemiology, PLoS Med5, e177.
25.
JiangY, SuZ, LiC, WangR, WenY, LiangH, HeJ, LiangW (2021) Association between the use of aspirin and risk of lung cancer: Results from pooled cohorts and Mendelian randomization analyses. J Cancer Res Clin Oncol147, 139–151.
26.
RosoffDB, SmithGD, LohoffFW (2021) Prescription opioid use and risk for major depressive disorder and anxiety and stress-related disorders: A multivariable mendelian randomization analysis. JAMA Psychiatry78, 151–160.
27.
CaiJ, HeL, WangH, RongX, ChenM, ShenQ, LiX, LiM, PengY (2022) Genetic liability for prescription opioid use and risk of cardiovascular diseases: A multivariable Mendelian randomization study. Addict117, 1382–1391.
28.
WuY, ByrneEM, ZhengZ, KemperKE, YengoL, MallettAJ, YangJ, VisscherPM, WrayNR (2019) Genome-wide association study of medication-use and associated disease in the UK Biobank. Nat Commun10, 1891.
29.
KunkleBW, Grenier-BoleyB, SimsR, BisJC, DamotteV, NajAC, BolandA, VronskayaM, Van Der LeeSJ, Amlie-WolfA, et al (2019) Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet51, 414–430.
SandersonE (2021) Multivariable Mendelian randomization and mediation, Cold Spring Harb Perspect Med11, a038984.
32.
RijnhartJJ, LampSJ, ValenteMJ, MacKinnonDP, TwiskJW, HeymansMW (2021) Mediation analysis methods used in observational research: A scoping review and recommendations. BMC Med Res Methodol21, 1–17.
33.
HigginsDM, MartinAM, BakerDG, VasterlingJJ, RisbroughV (2018) The relationship between chronic pain and neurocognitive function: A systematic review. Clin J Pain34, 262.
34.
AlbuCV, PadureanuV, BoldeanuMV, BumbeaAM, EnescuAS, AlbulescuDM, SilosiCA, EnescuA (2018) Vascular neurocognitive disorders and the vascular risk factors. J Mind Medl Sci5, 7–15.
35.
SalisF, LoddoS, ZandaF, PeraltaMM, SerchisuL, MandasA (2022) Comprehensive Geriatric Assessment: Application and correlations in a real-life cross-sectional study. Front Med9, 984046.
36.
ElsworthB, LyonM, AlexanderT, LiuY, MatthewsP, HallettJ, BatesP, PalmerT, HaberlandV, SmithG, ZhengJ, HaycockP, GauntTR, HemaniG The MRC IEU OpenGWAS data infrastructure. BioRxiv. doi: https://doi.org/10.1101/2020.08.10.244293.
EvangelouE, WarrenHR, Mosen-AnsorenaD, MifsudB, PazokiR, GaoH, NtritsosG, DimouN, CabreraCP, KaramanI, et al. (2018) Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet50, 1412–1425.
42.
Global Lipids Genetics Consortium. (2013) Discovery and refinement of loci associated with lipid levels. Nat Genet45, 1274.
43.
VaucherJ, KeatingBJ, LasserreAM, GanW, LyallDM, WardJ, SmithDJ, PellJP, SattarN, Paré G, HolmesMV (2018) Cannabis use and risk of schizophrenia: A Mendelian randomization study. Mol Psychiatry23, 1287–1292.
44.
PapiolS, SchmittA, MaurusI, RossnerMJ, SchulzeTG, FalkaiPJ (2021) Association between physical activity and schizophrenia: Results of a 2-sample Mendelian randomization analysis. JAMA Psychiatry78, 441–444.
45.
BurgessS, DaviesNM, ThompsonSG (2016) Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol40, 597–608.
46.
HemaniG, TillingK, SmithGD (2017) Orienting the causal relationship between imprecisely measured traits using GWAS summary data, PLoS Genet13, e1007081.
47.
VerbanckM, ChenC-y, NealeB, DoR (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet50, 693–698.
48.
ZhuX (2020) Mendelian randomization and pleiotropy analysis. Quant Biol10, 1–11.
49.
HemaniG, BowdenJ, SmithGD (2018) Evaluating the potential role of pleiotropy in Mendelian randomization studies, Hum Mol Genet27, R195–R208.
50.
ZhuX, LiX, XuR, WangT (2021) An iterative approach to detect pleiotropy and perform Mendelian Randomization analysis using GWAS summary statistics. Bioinform37, 1390–1400.
51.
GrecoM FD, MinelliC, SheehanNA, ThompsonJR (2015) Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med34, 2926–2940.
52.
BowdenJ, GrecoM FD, MinelliC, ZhaoQ, LawlorDA, SheehanNA, ThompsonJ, SmithGD (2019) Improving the accuracy of two-sample summary-data Mendelian randomization: Moving beyond the NOME assumption. Int J Epidemiol48, 728–742.
53.
BurgessS, ThompsonSG (2017) Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol32, 377–389.
54.
SandersonE, SmithGD, WindmeijerF, BowdenJ (2019) An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol48, 713–727.
55.
BurgessS, ThompsonSG (2015) Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol181, 251–260.
56.
ReesJM, WoodAM, BurgessS (2017) Extending the MR-Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy. Stat Med36, 4705–4718.
57.
BowdenJ, SmithGD, HaycockPC, BurgessS (2016) Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol40, 304–314.
58.
DeCarliC (2021) The link between blood pressure and Alzheimer’s disease. Lancet Neurol20, 878–879.
59.
IwagamiM, QizilbashN, GregsonJ, DouglasI, JohnsonM, PearceN, EvansS, PocockS (2021) Blood cholesterol and risk of dementia in more than 1· 8 million people over two decades: A retrospective cohort study, Lancet Healthy Longev2, e498–e506.
60.
MogulA, LeppienEE, LaughlinE, SpinlerSA (2021) Aspirin for primary prevention of cardiovascular disease: A review of recent literature and updated guideline recommendations. Expert Opin Pharmacother22, 83–91.
61.
HardyJ, SelkoeDJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science297, 353–356.
62.
ChandraS, JanaM, PahanK (2018) Aspirin induces lysosomal biogenesis and attenuates amyloid plaque pathology in a mouse model of Alzheimer’s disease via PPARα. J Neurosci38, 6682–6699.
63.
DouiriA, McKevittC, EmmettES, RuddAG, WolfeCDA (2013) Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation128, 1341–1348.
64.
PatronoC, BaigentC (2019) Role of aspirin in primary prevention of cardiovascular disease. Nat Rev Cardiol16, 675–686.
DudbridgeF, NewcombeP (2019) Replication and metaanalysis of genome-wide association studies. Handbook of Statistical Genomics: Two Volume Set, pp. 631–650.
67.
BurgessS, ButterworthA, ThompsonSG (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol37, 658–665.
68.
DaviesNM, HolmesMV, SmithGD (2018) Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians, BMJ362, k601.
